Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | C1S | P09871 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | F12 | P00748 | 1/20 | 0.30 |
| ▸ | F7 | P08709 | 1/20 | 0.30 |
| ▸ | F3 | P13726 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28160872 | 0.82 | PRSS1 (0.34) | LMNAPRSS1PRSS2C1SPRSS3 | |
| SCHEMBL1975862 | 0.78 | KDM4E (0.50) | RECQLKMT2A | |
| SCHEMBL8133375 | 0.77 | PRSS1 (0.36) | PRSS1PRSS2C1SPRSS3RECQL | |
| SCHEMBL1947313 | 0.77 | PRSS1 (0.31) | PRSS1PRSS2C1SPRSS3RECQL | |
| SCHEMBL7987220 | 0.77 | LMNA (0.34) | LMNAPRSS1PRSS2C1SPRSS3 | |
| SCHEMBL3835497 | 0.72 | PRSS1 (0.31) | PRSS1PRSS2C1SPRSS3RECQL | |
| SCHEMBL3833499 | 0.72 | LMNA (0.34) | LMNAPRSS1PRSS2C1SPRSS3 | |
| SCHEMBL8163828 | 0.72 | CES2 (0.31) | — | |
| SCHEMBL7989399 | 0.72 | PRSS1 (0.37) | PRSS1PRSS2PRSS3F10F7 | |
| SCHEMBL16798362 | 0.72 | KMT2A (0.36) | PRSS1PRSS2C1SPRSS3RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1110968-B1 | Intermediate for the preparation of Thrombininhibitors as anticoagulant agents | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | claimed |
| US-6552038-B1 | For use as thrombin inhibitors, coagulation inhibitors and agents for therapy of thromboembolic disorders | ELI LILLY AND COMPANY | 2003-04-22 | — | — | US | claimed |
| US-6534650-B2 | Thrombin inhibitors | ELI LILLY AND COMPANY | 2003-03-18 | — | — | US | claimed |
| EP-0816376-B1 | Trombin inhibitors as anticoagulant agents | LILLY CO ELI (US) | 2002-11-06 | — | — | EP | claimed |
| US-20010018423-A1 | Anticoagulant agents | KLIMKOWSKI VALENTINE J (US) | 2001-08-30 | — | — | US | claimed |
| EP-1110968-A1 | Thrombininhibitors as anticoagulant agents | Eli Lilly & Company (US) | 2001-06-27 | — | — | EP | claimed |
| US-6200967-B1 | USED AS THROMBIN INHIBITORS, COAGULATION INHIBITORS AND AGENTS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | ELI LILLY AND COMPANY | 2001-03-13 | — | — | US | claimed |
| US-6160176-A | Anticoagulant agents | ELI LILLY AND COMPANY (US) | 2000-12-12 | — | — | US | claimed |
| US-6034104-A | CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 2000-03-07 | — | — | US | claimed |
| US-5863929-A | ADMINISTERING ORTHO-HYDROXYBENZAMIDINE DERIVATIVES AS ANTITHROMBIN AGENT | ELI LILLY AND COMPANY (US) | 1999-01-26 | — | — | US | claimed |
| EP-0816376-A1 | Trombin inhibitors as anticoagulant agents | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| WO-1997049404-A1 | ANTICOAGULANT AGENTS | ELI LILLY AND COMPANY (US) | 1997-12-31 | — | — | WO | claimed |
| CN-101405275-A | Triazolone Derivatives | EISAI R&D MAN CO LTD (JP) | 2009-04-08 | — | — | CN | disclosed |
| US-20050267123-A1 | 6-Membered heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-12-01 | — | — | US | disclosed |
| US-6969715-B2 | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1438292-A1 | 6-MEMBERED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6008367-A | NITRILE AND AMINO SUBSTITUTED ISOOXAZOLE DERIVATIVE | ELI LILLY AND COMPANY (US) | 1999-12-28 | — | — | US | disclosed |
| US-5863929-A | ADMINISTERING ORTHO-HYDROXYBENZAMIDINE DERIVATIVES AS ANTITHROMBIN AGENT | ELI LILLY AND COMPANY (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0816376-A1 | Trombin inhibitors as anticoagulant agents | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997049404-A1 | ANTICOAGULANT AGENTS | ELI LILLY AND COMPANY (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267123-A1 | 6-Membered heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, SERPINC1 | LMNA 1275/4885PRSS1 55/4885PRSS2 119/4885 |
| US-20010018423-A1 | Anticoagulant agents | SERPINC1, F12, F11 | LMNA 507/4885PRSS1 328/4885PRSS2 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.